Table 5 Correlation of STAT3 polymorphisms with clinical characteristics of cases with breast cancer

rs744166

 AA

1

1

1

1

1

1

1

 AG

2.20 (0.39–12.33)

1.03 (0.38–2.80)

2.23 (1.05–4.71)

0.94 (0.39–2.30)

0.74 (0.33–1.65)

1.87 (0.83–4.23)

2.10 (0.64–6.83)

 GG

0.76 (0.33–1.72)

1.02 (0.32–3.19)

2.01 (0.84–4.83)

1.01 (0.36–2.80)

0.61 (0.23–1.57)

2.97 (1.08–8.13)

1.42 (0.37–5.54)

p:0.46

IDC vs others p:1

Grade I and II vs III p:0.0373

p:0.99

p:0.57

p:0.0323

Triple negative vs others p:0.4

 AA–GG

1

1

1

1

1

1

1

 AG

1.24 (0.35–5.03)

1.02 (0.45–2.32)

1.60 (0.85–3.01)

0.94 (0.45–1.94)

0.94 (0.48–1.83)

1.13 (0.57–2.25)

1.72 (0.72–4.09)

p:0.76

p:0.96

p:0.14

p:0.87

p:0.86

p:0.73

p:0.21

rs2293152

 GG

1

1

1

1

1

1

1

 GC

2.50 (0.55–11.83)

1.20 (0.52–2.75)

1.05 (0.54–2.03)

1.24 (0.58–2.67)

0.71 (0.35–1.42)

1.57 (0.77–3.23)

2.05 (0.80–5.23)

 CC

0.54 (0.50–6.21)

7.99 (0.45–140.47)

0.62 (0.21–1.82)

0.83 (0.21–3.34)

0.42 (0.11–1.66)

3.40 (0.70–16.48)

2.07 (0.47–9.09)

p:0.31

p:0.065

p:0.63

p:0.77

p:0.35

p:0.17

p:0.28

 GG–CC

1

1

1

1

1

1

1

 GC

2.83 (0.67–11.88)

1.94 (0.41–2.14)

1.14 (0.61–2.14)

1.28 (0.62–2.66)

0.80 (0.41–1.58)

1.34 (0.67–2.69)

1.76 (0.75–4.15)

p:0.15

p:0.88

p:0.68

p:0.51

p:0.52

p:0.41

p:0.19

rs4796793

 GG

1

1

1

1

1

1

1

 GC

1.42 (0.32–6.36)

0.47 (0.19–1.20)

0.77 (0.39–1.51)

1.93 (0.87–4.30)

1.48 (0.72–3.02)

1.56 (0.72–3.38)

1.96 (0.81–4.75)

 CC

0.47 (0.40–4.94)

0.37 (0.10–1.42)

0.59 (0.20–1.73)

1.92 (0.56–6.58)

1.11 (0.34–3.67)

0.30 (0.09–0.95)

0.21 (0.01–3.88)

p:0.64

p:0.19

p:0.57

p:0.23

p:0.56

p:0.0281

p:0.09

 GG–CC

1

1

1

1

1

1

1

 GC

1.65 (0.40–6.88)

0.60 (0.26–1.38)

0.86 (0.46–1.62)

1.67 (0.80–3.49)

1.45 (0.73–2.85)

1.98 (0.95–4.12)

2.43 (1.01–5.82)

p:0.49

p:0.23

p:0.64

p:0.17

p:0.29

p:0.062

p:0.0397